newsfilter
← Earnings
Earnings Releases·

MiNK Therapeutics — Third Quarter 2026 Earnings Summary

  • Recognized first pre-commercial product revenue of $0.2 million from the agenT-797 named-patient program; net loss narrowed 23% year-over-year to $2.6 million ($0.50 per share) for the quarter, driven by a 44% decline in general and administrative expenses.
  • U.S. dosing for the randomized Phase 2 ARDS trial (C-1300-02) is targeted to begin before year-end 2026 with data expected in the second half of 2027; first patient dosing for the University of Wisconsin GvHD prevention study is also expected by December 2026.
  • Selected for ARPA-H's BoSS program to advance room-temperature stabilization technology, adding to four existing non-dilutive funding sources while maintaining $7.5 million in cash and cash equivalents.
  • Management characterized the quarter as the "most capital-efficient" of 2026, with plans to advance the ARDS trial as an adaptive study and meet with the FDA before year-end regarding regulatory designations.
Company
MINK THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology